Biotechnology

Rallybio

Rallybio released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 212K (forecast USD 0), actual EPS USD -1.46 (forecast USD -1.2)

Candid Therapeutics Terminates Merger Agreement with Rallybio and Signs New Agreement with UCB

Rallybio released FY2025 earnings on March 16 (EST), actual revenue USD 858 K (forecast USD 733.33 K), actual EPS USD -1.5948 (forecast USD -3.0666)

Rallybio released FY2025 Q4 earnings on March 16 (EST), actual revenue USD 222K (forecast USD 133.33K), actual EPS USD -1.0297 (forecast USD -1.1733)

Rallybio released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 212 K (forecast USD 66.67 K), actual EPS USD 2.8435 (forecast USD -1.7066)

Rallybio released FY2025 9 Months earnings on November 6, 2025 (EST), with actual revenue of USD 636 K and actual EPS of USD -0.5739

Rallybio Exceeds Q3 2025 Revenue and EPS Expectations

Clark-Gartner's High Success Rate in Healthcare Stock Recommendations

Rallybio released FY2025 Semi-Annual earnings on August 7, 2025 (EST), with actual revenue of USD 424K and EPS of USD -3.4175

Rallybio released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 212K, actual EPS USD -1.731 (forecast EPS USD -1.8933)

Rallybio Sells REV102 Project Rights to Recursion

Rallybio Signs New Employment Agreement with Chief Medical Officer

Rallybio Initiates Drug Research for Immune Mediated Platelet Transfusion Refractoriness

Rallybio released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 212K (forecast USD 0), actual EPS USD -1.6864 (forecast USD -2.08)

Jones Trading downgrades Rallybio's stock rating

Rallybio Discontinues RLYB212 Project, Focuses on Development of RLYB116

Rallybio released FY2024 annual earnings on March 13 (EST), actual revenue USD 636 K (forecast USD 674.5 K), actual EPS USD -10.6143 (forecast USD -11.36)

Rallybio released FY2024 Q4 earnings on March 13 (EST), actual revenue USD 38 K (forecast USD 75 K), actual EPS USD -1.9782 (forecast USD -2.3)

Rallybio Corp signs revised sales agreement and reduces stock sale amount to $9.55 million

Rallybio Fourth Quarter Financial Performance Report

VS MEDIA

Big Tree Cloud

Tianci

Fold

Pop Culture

ChowChow Cloud

Autozi Internet Tech Global

Hitek Global Inc.

Global Engine

TMHC

SUNE

RLYB

ASRT

Halper Sadeh LLC is investigating SUNation Energy, Rallybio, Assertio Holdings, and Taylor Morrison Home for potential breaches of fiduciary duties in their respective merger or sale transactions. The firm alleges insiders may receive unfair benefits and seeks to protect shareholder interests by potentially seeking increased consideration or additional disclosures.

PR Newswire

Taylor Morrison Home

SUNation Energy

Assertio

Berkshire Hathaway

Berkshire Hathaway B

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

LIXT

Lixte Biotechnology Holdings (LIXT) announced a strategic pivot from oncology to AI energy infrastructure. The board appointed Stuart D. Porter, an energy investor, as director. The company will transform into an AI power solutions platform for data centers, seeking acquisitions in advanced generation tech while looking for a partner for its existing cancer therapy operations.

Tip Ranks

Lixte Biotechnology

Lixte Biotechnology Shifts Strategy to AI Energy Infrastructure

EWTX

This week saw three major deals in rare disease investment: Eli Lilly licensed Hanmi's GLP-2 therapy sonefpeglutide for up to $1.935 billion; Servier acquired Edgewise Therapeutics' muscular dystrophy program for up to $2.65 billion; and Avenzo merged with Rallybio, raising $215 million to advance its oncology pipeline.

Pharmexec

Edgewise Therapeutics

Eli Lilly

<![CDATA[Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio]]>

IBBQ

LABU

Adar1 Capital Management, a major shareholder of Rallybio Corporation (NASDAQ:RLYB), purchased 10,200 shares at $13.98 each, totaling $142,596. This acquisition increased their stake by 1.11%, bringing their total ownership to 926,352 shares valued at approximately $12.95 million. The transaction was disclosed to the SEC, as required for major shareholders. Rallybio's stock rose 2.7% to $14.58 during midday trading.

Market Beat

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Global Healthcare

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

iShares US Pharma

VG Health

Ark Genomic Revolution ETF

Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Buys 10,200 Shares of Stock

Rallybio Corporation's major shareholder, Adar1 Capital Management, acquired 800 shares at $13.83 each, totaling $11,064, increasing their stake by 0.10%. This follows a series of recent purchases, including 50,000 shares at $14.00 each. Despite the insider buying activity, Rallybio reported a quarterly loss of $1.46 per share, missing analyst expectations, and currently holds an average Sell rating. The stock is trading near a 52-week high, with a market cap of $75.91 million and a PE ratio of -5.61.

Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 Shares

Earnings Watch

Rallybio | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 212 K

Rallybio (NASDAQ:RLYB) is set to announce its Q1 2026 earnings on May 12, with analysts predicting a loss of $1.20 per share and revenue of $0.227 million. The company recently reported a loss of $1.03 per share for Q1 2025, exceeding estimates. Rallybio's stock has seen a slight decline, trading at $14.05, with a market cap of $74.35 million. Institutional investors hold 90.34% of the stock. Despite a recent upgrade to a "hold" rating, the consensus remains a "sell" among analysts. Rallybio focuses on therapies for rare genetic diseases.

Rallybio (RLYB) Projected to Post Quarterly Earnings on Tuesday

Rallybio(RLYB.US)